◎ Received the first technology transfer proposal.

In 2019, prior to filing our patent, we conducted in vitro experiments at the SK Bioland Research Institute, yielding exceptional results. Following this, we carried out in vivo animal testing at the Sahmyook University College of Pharmacy. Upon the conclusion of the trials in December, the supervising professor informed me that our results were highly favorable when compared to 5% Minoxidil. Furthermore, every student involved in the research described the outcomes as truly extraordinary.

Merely a week after receiving those results—and before a patent application had even been filed—I was offered a technology transfer deal by a corporation, proposing an upfront lump sum of [00] billion KRW plus royalties. I politely declined. It is exceedingly rare for an individual inventor to be offered such a massive lump sum. That fact alone allows even someone with no scientific background to easily gauge just how groundbreaking those animal test results were.

The truth is, I had already recognized its remarkable efficacy against hair loss as early as 2017, witnessing my family, relatives, and friends using it firsthand. In essence, long before formal academic studies, I had already seen the high probability of conquering hereditary hair loss through real-world clinical application. Back in 2019, while I believed I had found the solution, I lacked the 100% certainty required to declare it publicly. Today, however, that has changed. Regardless of the time or place, I can now state with absolute, 100% confidence that human hereditary hair loss has been conquered.